- Will the industry consolidate, decentralize, or undergo a bimodal transformation?
- How will the current trends affect the major market segments? - Which companies will enter the market and which will not survive? This new 83-page report from VPGMarketResearch analyzes strategies, marketing tactics and technological know-how of the world's leading animal health companies, including: Five-year forecasts for: - Major market segments - Key geographic regions Company Profiles Bayer Animal Health - Considering selling animal health division - Plans to invest in Kiel - Rising demand for collars - Focusing on parasiticides and anti-infectives - Strong position in parasiticides - Animal health R&D - Worldwide marketing network - Emerging markets - Re-registering existing products - Present structure - Diverse businesses - Challenged by animal disease outbreaks - Europe's premier research organization - Animal health R&D - Crop science segment - Monsanto acquisition - Chairman Werner Baumann - Supervisory board Boehringer Ingelheim - Sales and growth - Animal health is one of the major pillars - Swine vaccine Ingelvac circoflex - Merial animal health - U.S. animal health market position - Promoting Eqvalan line - Seeking to reinforce position in livestock market - Strategies supported by collaborations - Merial R&D programs - Collaborative efforts - Porcine Reproductive and Respiratory Syndrome (PRRS) - Decentralized R&D Ceva - Sales, growth and R&D investment - Biomune, Phylaxia and French sites - 2016 acquisitions - Hatcher automation and in-ovo vaccination - India acquisition - Brazil--important strategic market - Merial swine vaccines acquisition Elanco Animal Health - Strong technological base - Fermentation and chemical synthesis - Strong base in antibiotics and anticoccidials - Expiration of patents caused restructuring - US marketing - Lilly Japan - Focused marketing strategies - Well-established relationship with customers - Multi-disciplinary business with diverse product portfolio - In the midst of strategic decisions - Stepping up efforts to curtail time to market - Could divest animal health - Changed product mix - Strategic collaborations - Broadening portfolio of companion animal medicines - Hard look at bottom line - CEO Dave Ricks Merck Animal Health - Sales and growth - Higher sales of Bravecto - Vallée acquisition - Extensive know-how in animal health - Sphereon technology - Expanding worldwide poultry business - Poultry biological research laboratories - Segmented poultry-product line - Mitigated generic competition - R&D productivity improving - Patents, economies of scale, and powerful intellectual base - Keytruda key to future Phibro Animal Health - Sales and growth - Extensive portfolio of antibiotics and antibacterials - Sales force, sales offices and distribution network - Animal health R&D facilities - Biotay acquisition Virbac - Sales and growth - Eli Lilly dog parasiticides acquisition - Product portfolio - Formulation know-how - Waltham nutrition products - Reorganized European distribution - Decentralized approach for food-producing animals - Benefitting from new companion animal products - Focusing on niche markets - Seeking expansion in the U.S. Zoetis - Majority of revenue from production animals - Largest market share in the industry - Poultry and swine revenue declining - Scale allows to use own sales force in emerging markets - Management continues cost-cutting efforts - Reassessing manufacturing infrastructure - CEO Juan Ramon Alaix - Market-leading position in emerging markets - Leading share in Asia-Pacific, Canada and Latin America - Fragmented customer base - Leading position in fastest-growing markets
Contains 83 pages and 6 tables
|